Lindbrook Capital’s Kymera Therapeutics KYMR Stock Holding History

Lindbrook Capital’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$7.39K	Buy	270 +108	+67%	+$3.94K	﹤0.01%	1784
2024 Q4	$6.52K	Hold	162	–	–	﹤0.01%	1864
2024 Q3	$7.67K	Sell	162 -5	-3%	-$221	﹤0.01%	1813
2024 Q2	$4.99K	Buy	167 +16	+11%	+$554	﹤0.01%	1992
2024 Q1	$6.07K	Hold	151	–	–	﹤0.01%	1805
2023 Q4	$3.84K	Buy	151 +77	+104%	+$1.38K	﹤0.01%	2023
2023 Q3	$1.03K	Buy	+74	New	+$1.49K	﹤0.01%	2352
2023 Q1	–	Sell	-12	Closed	-$300	–	2853
2022 Q4	$300	Hold	12	–	–	﹤0.01%	2678
2022 Q3	$0	Hold	12	–	–	﹤0.01%	2773
2022 Q2	$0	Buy	+12	New	+$280	﹤0.01%	2630

Other funds holding KYMR

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Lindbrook Capital's KYMR Position: Q1 2025 in Review

Lindbrook Capital increased its Kymera Therapeutics (KYMR) stake by 67% in Q1 2025, buying an estimated $3.94K and bringing the position to 270 shares worth $7.39K. The position accounts for ﹤0.01% of the portfolio, ranked #1784.

Lindbrook Capital first reported a position in KYMR in Q2 2022 and has held it in 10 quarters since. The position peaked at $7.67K in Q3 2024. 173 funds tracked by Wall St. Rank hold KYMR as of Q1 2025.

Lindbrook Capital held 270 shares of Kymera Therapeutics worth $7.39K as of Q1 2025.
Lindbrook Capital bought 108 Kymera Therapeutics shares in Q1 2025, an estimated $3.94K.
Kymera Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1784 holding.
Lindbrook Capital first reported a position in Kymera Therapeutics in Q2 2022 and has held it in 10 quarters since.
Lindbrook Capital's Kymera Therapeutics position peaked at $7.67K in Q3 2024.
173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.